Cambium Bio LtdASX: CMB

Change in Substantial Holding

Sep 15, 2026 at 7:51 PM EDT · Issued by Cambium Bio Ltd via ASX

Filed with ASX · Sep 15, 2026 at 7:51 PM EDT · 5 pages · English

On 6ix: 6ix.com/news/change-in-substantial-holding-194

Release

Unit 2.06/31 Lexington Drive, BELLA VISTA, NSW 2153 Ph: 1300 995 098 • www.cambium.bio • ABN 13 127 035 358 16 September 2026 Market Announcements Office ASX Limited Level 27, 39 Martin Place, Sydney NSW Dear Sir/Madam, Re: Late Lodgement of Notices of Change of Interests of...

Cambium Bio Ltd on 6ix

Earlier from Cambium Bio

Update - Proposed issue of securities - CMBSep 1
Notification regarding unquoted securities - CMBSep 1
Proposed issue of securities - CMBAug 31
FY26 Appendix 4E and Annual ReportAug 28
FY26 Appendix 4G and Corporate Governance StatementAug 28

Later from Cambium Bio

Notice of ceasing to be a substantial holderSep 15
Cambium Bio Secures A$10.85 Million Funding PackageSep 15
Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye DiseaseSep 16
Notification of cessation of securities - CMBSep 23
Date of AGM and Closing Date for Director NominationsSep 27

All Cambium Bio news releases

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio